A Screening Study for the Development of Simvastatin-Doxorubicin Liposomes, a Co-Formulation with Future Perspectives in Colon Cancer Therapy

An increasing number of studies published so far have evidenced the benefits of Simvastatin (SIM) and Doxorubicin (DOX) co-treatment in colorectal cancer. In view of this, the current study aimed to investigate the pharmaceutical development of liposomes co-encapsulating SIM and DOX, by implementing...

Descripción completa

Detalles Bibliográficos
Autores principales: Barbălată, Cristina Ioana, Porfire, Alina Silvia, Sesarman, Alina, Rauca, Valentin-Florian, Banciu, Manuela, Muntean, Dana, Știufiuc, Rareș, Moldovan, Alin, Moldovan, Cristian, Tomuță, Ioan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537800/
https://www.ncbi.nlm.nih.gov/pubmed/34683821
http://dx.doi.org/10.3390/pharmaceutics13101526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537800/
https://www.ncbi.nlm.nih.gov/pubmed/34683821
http://dx.doi.org/10.3390/pharmaceutics13101526

Ejemplares similares